Clinical Trial: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07017725) titled 'A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia' on June 04.

Brief Summary: The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:

* To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103.

* To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to s...